LY-2090314 | LY2090314 | CAS#603288-22-8 | GSK-3 inhibitor

MedKoo Cat#: 205518 | Name: LY2090314

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) which plays an important role in many pathways, including initiation of protein synthesis, cell proliferation, cell differentiation, and apoptosis. Pre-clinically LY2090314 i stabilizes β-catenin and enhances the efficacy of platinum based regimens.

Chemical Structure

LY2090314

CAS#603288-22-8

Theoretical Analysis

MedKoo Cat#: 205518

Name: LY2090314

CAS#: 603288-22-8

Chemical Formula: C28H25FN6O3

Exact Mass: 512.1972

Molecular Weight: 512.53

Elemental Analysis: C, 65.61; H, 4.92; F, 3.71; N, 16.40; O, 9.36

Price and Availability

Size	Price	Availability
5mg	USD 110.00	Ready to ship
10mg	USD 185.00	Ready to ship
25mg	USD 385.00	Ready to ship
50mg	USD 650.00	Ready to ship
100mg	USD 1,150.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

LY2090314; LY-2090314; LY 2090314.

IUPAC/Chemical Name

3-(9-fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione

InChi Key

HRJWTAWVFDCTGO-UHFFFAOYSA-N

InChi Code

InChI=1S/C28H25FN6O3/c29-18-12-17-15-34(28(38)32-7-3-1-4-8-32)11-10-33-16-20(19(13-18)25(17)33)23-24(27(37)31-26(23)36)21-14-30-22-6-2-5-9-35(21)22/h2,5-6,9,12-14,16H,1,3-4,7-8,10-11,15H2,(H,31,36,37)

SMILES Code

O=C(C(C1=CN2C3=C1C=C(F)C=C3CN(C(N4CCCCC4)=O)CC2)=C5C6=CN=C7C=CC=CN76)NC5=O

Appearance

Off-white to light yellow solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#BBC50731

QC Data

View QC data: current batch, Lot#BBC50731

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.

In vitro activity:

Several assays and imaging techniques were utilized to determine cellular growth patterns of 3 NB cell lines (NGP, SK-N-AS, and SH-SY-5Y) treated with LY2090314 or Tideglusib. Cells were plated and treated with LY2090314 in increasing nanomolar concentrations (20 nM, − 1000 nM), and proliferation was recorded using a colorimetric, MTT assay at 48 h, 72 h, and 96 h (Fig. 1). In Fig.1a, a steep reduction on average of 23% at 48 h, 42% at 72 h, and 61% at 96 h was noted in NGP cells treated with 20 nM of LY2090314. At higher concentrations of 25 nM – 1000 nM LY2090314 in the same cells, there was a more gradual reduction in cell growth, whereas, at 1000 nM a 37% reduction was seen at 48 h, 57% at 72 h, and 75% at 96 h. dditionally, a substantial decrease of 22 - 61% can be seen with the much lower concentrations of 20 nM of LY2090314 at 96 h in NGP, SK-N-AS, and SH-SY-5Y cells. SKN-AS and SH-SY-5Y both showed similar decreases in growth, and like NGP, lower concentrations of LY2090314 in the nanomolar range more significantly inhibited growth compared to the micromolar range of Tideglusib. In summary, MTT assay data showed a significant decrease in cellular proliferation in all 3 cell lines treated with LY2090314 at concentrations of 20, 25, 50, 100, and 1000 nM during 48, 72, and 96 h. To confirm MTT results, CFU assays were performed in all cell lines with increasing concentrations of LY2090314 (10 nM – 50 nM) which showed a reduction in NB cells ability to form colonies (Fig. 2a). Lastly, to examine confluency of cells, Incucyte imaging data was collected every 3 h up to 4 days and graphed (Fig.2b). Decreasing confluency over time is noted in all cell lines treated with increasing concentrations of LY2090314. This is the first study in NB (neuroblastoma), and LY2090314 is a potential agent for the treatment of NB in future. Reference: BMC Cancer. 2018; 18: 560. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5948712/

In vivo activity:

It was sought to assess the ability of LY2090314 to activate the Wnt pathway in vivo and subsequently question if pathway elevation could lead to antitumor efficacy in melanoma. In mouse, LY2090314 is rapidly cleared and has a plasma half-life of 36 minutes (Fig 5A). In studies assessing the in vivo gene expression of Axin2, a Wnt responsive gene, a significant induction of Axin2 mRNA at 2 and 4 hours post dose of LY2090314 was observed in A375 xenograft tumor tissue (Fig 5B). This finding is in agreement with the in vitro experiments which also reveal Axin2 elevation 2–4 hours after initial drug exposure (Fig 1E). The rapid decline in Axin2 gene expression after 4 hours is consistent with the short half-life and pharmacokinetic properties of the compound in vivo (Fig 5A and 5B). Despite the transient elevation of the Wnt pathway with LY2090314 treatment, a single agent antitumor efficacy was able to be observed in subcutaneous A375 xenografts dosed every 3 days (Fig 5C, p<0.003). The in vitro and in vivo activity of LY2090314 in preclinical models suggests that the role of Wnt activators for the treatment of both BRAF and NRAS driven human melanoma should be further explored. Reference: PLoS One. 2015; 10(4): e0125028. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411090/

	Solvent	mg/mL	mM
Solubility
	DMSO	47.0	91.70
	Ethanol	1.1	2.20

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 512.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Kunnimalaiyaan S, Schwartz VK, Jackson IA, Clark Gamblin T, Kunnimalaiyaan M. Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro. BMC Cancer. 2018 May 11;18(1):560. doi: 10.1186/s12885-018-4474-7. PMID: 29751783; PMCID: PMC5948712. 2. Atkinson JM, Rank KB, Zeng Y, Capen A, Yadav V, Manro JR, Engler TA, Chedid M. Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3. PLoS One. 2015 Apr 27;10(4):e0125028. doi: 10.1371/journal.pone.0125028. PMID: 25915038; PMCID: PMC4411090. 3. Santoro R, Zanotto M, Simionato F, Zecchetto C, Merz V, Cavallini C, Piro G, Sabbadini F, Boschi F, Scarpa A, Melisi D. Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer. Mol Cancer Ther. 2020 Jan;19(1):247-257. doi: 10.1158/1535-7163.MCT-19-0270. Epub 2019 Sep 27. PMID: 31562256.

In vitro protocol:

In vivo protocol:

1. Santoro R, Zanotto M, Simionato F, Zecchetto C, Merz V, Cavallini C, Piro G, Sabbadini F, Boschi F, Scarpa A, Melisi D. Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer. Mol Cancer Ther. 2020 Jan;19(1):247-257. doi: 10.1158/1535-7163.MCT-19-0270. Epub 2019 Sep 27. PMID: 31562256. 2. Atkinson JM, Rank KB, Zeng Y, Capen A, Yadav V, Manro JR, Engler TA, Chedid M. Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3. PLoS One. 2015 Apr 27;10(4):e0125028. doi: 10.1371/journal.pone.0125028. PMID: 25915038; PMCID: PMC4411090.

1. A phase I dose-escalation, pharmacokinetic (PK), and pharmacodynamic (PD) evaluation of intravenous LY2090314 a GSK3 inhibitor administered in combination with pemetrexed and carboplatin. Meeting: 2011 ASCO Annual Meeting, Presenter: Les H. Brail.